Astrazeneca Pharma India formerly known as Astra-IDL (AIL), a joint venture of Astra Zeneca, UK and Hinduja controlled IDL is a market leader in local anesthetics with xylocaine. The, UB's 100% subsidiary, UB Biotek, has tied up with the Company to market its newly-patented anti-obesity nutraceutical. The herbal product, Hydroxycitrisol, extracted from garcinia (kokum), is one of two UB technologies to recently get US patents. It is due to complete clinical tests at AIL and may hit the market by this year-end. AIL is also due to get ayurvedic clearances from the Union Department of Indian Systems of Medicine while the US FDA approval is also pending. The revenue expenditure incurred during the financial year 1999-2000 and 2000-2001 on ERP implementation and US FDA certification is being treated as deferred revenue expenditure in the books of accounts of the the company. The ERP expenditure is being charged off in 3 equal annual instalments from the year in which it is incurred. The US FDA certification expenses will be amortised over a period of 3 years from the year in which such certification is obtained. The company has expanded the installed capacity of Injectables during the year 2001 by 0.20 crores(Nos) and with this expansion the total capacity has been increased to 2.40 crores(Nos). Astra Pharmaceuticals AB, Sweden recently acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital. Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden ( now known as AstraZeneca AB, Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company. The Company's marketing activities including medical services have been certified for ISO 9002. During 2001-02 the company has commissioned the automatic ampoule filling machine and thereby increased the capacity of the same from 10 Mio to 12 Mio. The company has launched during the year 2003,an Oncology product,Arimidex,for the management of breast cancer. The Pharmaceutical major Astrazeneca has decided to make its Astrazeneca India's R&D as a part of its global R&D organisation.The company has decided to expand its process R&D group in Bangalore.It has purchased 14200 Sq Mtr of land,which is a part of its "Avishkar" campus,where it has set up R&D centre.